Joyce Shoffner would never have predicted that Duke University, an institution she revered and at one time worked for, would put her in a breast cancer clinical trial testing a fraudulent technology.
“They advertised publicly that this science offered an 80 percent cure rate,” Shoffner said. “To have the type of cancer I had, I was just going to do that, there was nobody that was going to stop me, because this was what I was told and this was what I believed was going to happen.”
In July 2008, Shoffner became patient No. 1 in the trial that promised to choose the best therapy for the unique characteristics of her disease. Alas, the groundbreaking genomic predictors pioneered by Anil Potti and his mentor Joseph Nevins, which the trials were testing, would turn out to be fraudulent.
FDA Notifies 300 Medical Practices that they May Have Purchased Unapproved Prescription Drugs
FDA notified more than 300 medical practices that they may have purchased unapproved prescription drugs or injectable devices from a foreign supplier, Gallant Pharmaceutical International.
“Gallant and twelve individuals, including a doctor and an office manager, have been convicted for their roles in distributing drugs and devices that have not been approved or cleared by FDA in the U.S.,” the agency’s letter to the practices said. “The unapproved drugs and unapproved/uncleared devices sold by Gallant were obtained from foreign sources and shipped and stored outside of the regulated supply chain.”
The drugs sold include Avastin, Erbitux, Herceptin, Rituxan, and Velcade.
Four Cancer Charities Charged with Fraud in Raising $187 Million
The Federal Trade Commission charged four cancer charities with fraudulently raising $187 million between 2008 and 2012.
The federal complaint names Cancer Fund of America Inc., Cancer Support Services Inc., their president, James Reynolds, Sr., and their chief financial officer and CSS’s former president, Kyle Effler; Children’s Cancer Fund of America Inc. and its president and executive director, Rose Perkins; and The Breast Cancer Society Inc. and its executive director and former president, James Reynolds II.
CPRIT Awards 41 Grants, Totaling Over $89 Million
The Cancer Prevention and Research Institute of Texas awarded 28 grants through its academic research program, 11 grants through its prevention program and two grants through its product development research program.
Totaling over $89 million, the grants include nearly $31 million for six Core Facilities Support Awards. Additional research grants help support the recruitment of cancer scientists to academic institutions in Texas.
PCORI Approves $120 million in research grants
Catherine Brown named president of John Wayne Cancer Foundation
Community Oncology Alliance and Community Oncology Pharmacy Association appoints advisory board
- Meridian Health and Hackensack University Health Network sign definitive merger agreement
|Drugs and Targets|
FDA grants fast track designation to AG-120
Palmetto GBA issues draft LCD for Oncotype DX prostate cancer test
Baylor Research Institute and TGen extend collaboration